IL1B and COVID-19: The aim of the present study was to quantify the expression levels of the interleukin-1 receptor antagonist (IL–1Ra), the inflammatory cytokine IL–1β, oxidative stress markers, and baseline blood hematological parameters among patients with COVID-19 compared with a group of patients without SARS-CoV-2 infection.